Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.80 | 10.30 | 0.12% |
| CAC 40 | 8,057.36 | 142.00 | 1.79% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,857.06 | 116.26 | 0.24% |
| FTSE 100 | 10,412.24 | 162.72 | 1.59% |
| HKSE | 25,959.90 | 551.44 | 2.17% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,213.39 | 114.56 | 0.87% |
| S&P 500 | 6,807.19 | 11.20 | 0.16% |
| S&P/ASX 200 | 8,711.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |